Esperion Therapeutics, Inc. (ESPR)
| Previous close | 1.8700 |
| Open | 1.7800 |
| Bid | 1.8400 x 200 |
| Ask | 1.8500 x 100 |
| Day's range | 1.7100 - 1.9200 |
| 52-week range | 0.7000 - 3.4000 |
| Volume | |
| Avg. volume | 6,302,577 |
| Market cap | 349.445M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0300 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.41 |
GlobeNewswireEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) – – CLEAR Outcomes Sets New Standards for Diversity and Inclusion with Enrollment of 48% Women and 17% Hispanic/Latinx Patients – ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion
- GlobeNewswire
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m. ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration’s (FDA) recent approval of broad new labels for Esperion’s products. “We are honored to ring the Nasdaq opening bell to celebrate a significant milestone for Esperion,” said Mr. Koenig. “This ceremony marks an opportunit
ZacksWhy Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
